From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology

Annals of Nuclear Medicine

Volumn 15, Issue 6, 2001, Pages 471-486

  Kubota, Kazuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

11C methionine; 18 F fluorodeoxyglucose; 18F fluoromisonidazole; Autoradiography; Lung cancer; Positron emission tomography; Radiotherapy monitoring; Tumor diagnosis; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; GLUCOSE DERIVATIVE; METHIONINE C 11; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; BIOLOGY; CANCER CELL; CANCER DIAGNOSIS; CANCER RECURRENCE; CELL METABOLISM; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; ONCOLOGY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR;

EID: 0035708631     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988499     Document Type: Review

References (131)

1. PET imaging in oncology
2. PET in oncology 1-lung, breast, soft tissue sarcoma
3. PET in oncology 2-other tumors
4. Positron imaging in oncology: Present and future
5. FDG-PET in clinical oncology: Review and evaluation of results of a private clinical PET center
6. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
7. 18F]-FDG in oncology: A clinical update
8. On the origin of cancer cells
9. Comparative biochemistry of hepatomas IV. Isotope studies of glucose and fructose metabolism in liver tumors of different growth rates
10. FDG accumulation and tumor biology. Mini-review
11. Transport of sugars in tumor cell membranes
12. Elevated levels of glucose transporter and transporter messenger RNA are induced by ras or sac oncogenes
13. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription
14. Distribution of glucose transporters in human brain tumors
15. Over-expression of facilitative glucose transporter genes in human cancer
16. The effect of 2-deoxy-D-glucose on glycolysis and respiration of tumor and normal tissues
17. Inhibition of anaerobic glycolysis in ehrlich ascites tumor cells by 2-deoxy-D-glucose
18. Certain metabolic and pharmacologic effects in cancer patients given infusion of 2-deoxy-D-glucose
19. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat
20. 2. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose
21. 18F]2-deoxy-2-fluoro-D-glucose
22. 18F): Nontoxic tracer for rapid tumor detection
23. 18F]fluoro-D-glucose in liver metastasis from colon carcinoma
24. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models
25. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vivo
26. Recent advances in the analyses of the characteristics of tumors on FDG uptake
27. Intratumoral distribution of tritiated-FDG in breast carcinoma: Correlation between Glut- 1 expression and FDG uptake
28. Glucose transport and FDG uptake in untreated primary human non-small cell lung cancer
29. Comparative biochemistry of hepatoma V. Studies of amino acid incorporation in liver tumors of different growth rates
30. Transport of amino acid by confluent and nonconfluent 3T3 and polyoma virus-transformed 3T3 cells growing on glass cover slips
31. Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture
32. Methionine dependence in cancer cells-a review
33. Cancer diagnosis with positron computed tomography and carbon-11-labeled L-methionine
34. Lung tumor imaging by positron emission tomography using C-11-L-Methionine
35. Uptake of C-11 methionine in breast cancer studied by PET: And association with the size of S-phase fraction
36. Carbon-11-methionine PET imaging of malignant melanoma
37. Re-evaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo?
38. Methionine uptake by tumor tissue: A microautoradiographic comparison with FDG
39. 11C]methionine in human plasma
40. 11C]methionine uptake in tumor using positron emission tomography
41. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck
42. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake
43. 99mTc-MIBI and deoxyglucose in mouse breast cancer models
44. Active and passive mechanisms of [fluorine-18]fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: A microautoradiographic study
45. 18F]fluoro-D-glucose in human cancers heterotransplanted in nude mice: Comparison between histology and glycolytic status
46. Dose FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake
47. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy
48. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
49. Recurrence of colorectal tumors: PET evalutaion
50. Carbon-11-methionine uptake in squamous cell head and neck cancer
51. Cerebral gliomas: Evaluation with methionine-PET
52. Optimal scan time for fluorine-18-fluorodeoxyglucose positron emission tomography in breast cancer
53. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy
54. The dose uptake ratio as index of glucose metabolism: Useful parameter or over simplification?
55. Advantage of delayed imaging of whole-body FDG-PET for tumor detection
56. Serum glucose: Effects on tumor and normal tissue accumulation of 2-[F18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma
57. 18F-2-fluoro-2-deoxy-D-glucose
58. Re-evaluation of myocardial FDG uptake in hyperglycemia
59. 18F]fluorodeoxyglucose PET with glucose loading
60. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas
61. Influence of the blood glucose concentration on FDG uptake in cancer-a PET study
62. Head and neck cancer: Effect of food ingestion on uptake of C-11 methionine
63. Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose into experimental mammary carcinoma
64. Differential diagnosis of lung tumor with positron emission tomography: A prospective study
65. PET in lung cancer
66. Cancer detection with whole-body positron emission tomography using fluorodeoxyglucose
67. Diagnostic value of whole-body positron emission tomography using fluorine-18-fluorodeoxyglucose for lung cancer
68. Preoperative staging of non-small cell lung cancer with positron emission tomography
69. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
70. Staging non-small cell lung cancer with whole-body PET
71. PET imaging of nonsmall-cell lung carcinoma with carbon-11-methionine: Relationship between radioactivity uptake and flowcytometric parameters
72. 11C-methionine for the detection of hilar and mediastinal lymph node metastasis of lung cancer
73. Feasibility of fluorine-18 fluorophenylalanine for body tumor imaging compared with L-methionine
74. 18F alpha-methyltyrosine PET studies in patients with brain tumors
75. Detection of malignant tumors: Whole-body PET with fluorine 18 α-methyl tyrosine versus FDG-preliminary study
76. 18F DOPA PET for detection of gastrointestinal carcinoid tumors
77. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma
78. FDG PET measurement of the proliferative potentional of non-small cell lung cancer
79. Fluorine-18-FDG imaging is negative in bronchioloalveolar lung carcinoma
80. 18F]-D-glucose
81. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer
82. 18F-FDG PET Imaging of muscle activity in runners
83. Skeletal muscle uptake of fluorine-18-FDG: Effect of oral diazepam
84. Speech-related visualization of laryngeal muscles with fluorine-18-FDG
85. Mapping energy metabolism in Haw and tongue muscles during chewing
86. Physiological FDG uptake in the palatine tonsils
87. Diffusely increased colonic F-18-FDG uptake in acute enterocolitis
88. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation
89. Gamut. Benign causes of 18-FDG uptake on whole body imaging
90. FDG PET of the retroperitoneum: Normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls
91. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11-methionine
92. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants
93. 18F]-fluorodeoxyglucose uptake in abdominal abscessed: A PET study
94. Evaluation of pulmonary lesions with positron emission tomography
95. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis
96. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography
97. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue
98. Autoradiographic evaluation of the intra-tumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma
99. FDG accumulation in tumor tissue
100. 11C-L-methionine tumor uptake to irradiation
101. 3H]thymidine and gallium-67
102. 11C]methionine; Feasibility for monitoring recurrence of tumor
103. Fluorodeoxyglucose cell incorporation as an index of cell proliferation: Evaluation of accuracy in cell culture
104. 18F-Fluorodeoxyglucose for the treatment evaluation of cancer with PET
105. Transient increase in glycolytic metabolism in cultured tumor cells immediately after exposure to ionizing radiation: From gene expression to deoxyglucose uptake
106. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: A PET study
107. Rapid rise in FDG uptake in an irradiated human tumour xenograft
108. Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses
109. Positron emission tomography for treatment evaluation and recurrence detection compared with CT in long follow-up cases of lung cancer
110. 11C]methionine: A preliminary study
111. 11C]methionine-positron emission tomography
112. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer
113. 18F]-2-deoxy-D-glucose
114. Detecting recurrent or residual lung cancer with FDG-PET
115. Recurrence of colorectal tumors: PET evaluation
116. Chest wall FDG accumulation in serial FDG-PET images in patients being treated for bronchogenic carcinoma with radiation (abstract)
117. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: A comparison of fluorodeoxyglucose, L-methionine and thymidine
118. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer
119. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnosis
120. 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck
121. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography
122. Comparison of FDG-PET and MRI/CT in detecting recurrence of head and neck cancer
123. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells
124. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18]fluoromisonidazole
125. 18F-fluoromisonidazole, deoxyglucose and methionine in tumour tissue distribution
126. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia
127. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: In vitro evaluation for PET imaging
128. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells
129. Hypoxia-induced increase in FDG uptake in MCF7 cells
130. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia